Skip to main
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 0%
Hold 67%
Sell 22%
Strong Sell 0%

Bulls say

RxSight is expected to continue its growth trajectory driven by its innovative light adjustable lenses technology, which offers a customized solution for patients following cataract surgery. Despite the current challenges in utilization and margin contraction, the company's strong financials, including a gross margin of 76.1% in Q1 2026, indicate its ability to weather the storm and return to growth in the second half of 2026. Exciting developments in the overseas market also present a potential growth opportunity for the company.

Bears say

RxSight is currently facing challenges in revenue growth, with lower Light Delivery Device revenue leading to a 19% decline in overall revenue in the fourth quarter of 2025. The company is also struggling with low LDD placements, with only 25 LDDs placed in the fourth quarter. While management has expressed optimism for future growth, there are concerns around limited adoption due to the need for additional capital equipment, potential competition in the market, and the possibility of a dilutive funding round. These factors, along with a high cash burn rate, contribute to the analyst's negative outlook on RxSight's stock.

RxSight (RXST) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 9 analysts, RxSight (RXST) has a Hold consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.